1-11 of 11
Marco Rocchi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Alessandro Isidori, MD PhD, Stefano Guidi, Potito Rosario Scalzulli, MD, Attilio Olivieri, MD, Emanuele Angelucci, Saveria Capria, MD, Francesca Patriarca, Barbara Castagnari, MD, Francesco Angrilli, MD, Daniele Vallisa, MD, Gerardo Musuraca, Andrea Mengarelli, MD, Piero Galieni, Gaudio Francesco, Patrizia Tosi, Pier Luigi Zinzani, MD PhD, Alberto Bosi, Donatella Baronciani, Nicola Cascavilla, MD, Barbara Guiducci, Cristina Clissa, MD, Elisa Gabucci, Marco Rocchi, Federica Loscocco, PhD, Giuseppe Visani, MD
Journal: Blood
Blood (2015) 126 (23): 1999.
https://doi.org/10.1182/blood.V126.23.1999.1999
Published: 2015
Journal Articles

Environmental Nanoparticles Are Significantly over-Expressed in Acute Myeloid Leukemia: a Novel Pathogenetic Cofactor?

Giuseppe Visani, MD, Anita Manti, Laura Valentini, Barbara Canonico, Federica Loscocco, PhD, Alessandro Isidori, MD PhD, Elisa Gabucci, Pietro Gobbi, Stefano Montanari, Marco Rocchi, Stefano Papa, Maria Antonietta Gatti, MD
Journal: Blood
Blood (2015) 126 (23): 4965.
https://doi.org/10.1182/blood.V126.23.4965.4965
Published: 2015
Journal Articles

Tosedostat Plus Low Dose Cytarabine Induces a High Rate of Responses That Can be Predicted By Genetic Profiling in Elderly AML

Giuseppe Visani, MD, Federica Loscocco, PhD, Fabio Fuligni, Eliana Zuffa, MD, Alberto Sensi, MD, Alfonso Zaccaria, MD, Gerardo Musuraca, MD, Barbara Giannini, Alessandro Lucchesi, Francesca Fabbri, Anna Maria Mianulli, Patrizia Tosi, MD, Michela Tonelli, Anna Candoni, MD, Renato Fanin, Giovanni Sparaventi, Marco Gobbi, MD, Marino Clavio, Marco Rocchi, Pier Paolo Piccaluga, MD PhD, Alessandro Isidori, MD PhD
Journal: Blood
Blood (2015) 126 (23): 329.
https://doi.org/10.1182/blood.V126.23.329.329
Published: 2015
Journal Articles

Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes

Federica Loscocco, PhD, Giuseppe Visani, MD, Elisa Giacomini, Annamaria Ruzzo, Sara Galimberti, MD, Maria Teresa Voso, MD PhD, Carlo Finelli, MD, Elena Ciabatti, Emiliano Fabiani, Francesco Graziano, Sara Barulli, Antonio Volpe, MD, Domenico Magro, Pier Paolo Piccaluga, MD PhD, Fabio Fuligni, Marco Vignetti, Paola Fazi, Alfonso Piciocchi, Cristina Clissa, MD, Elisa Gabucci, Marco Rocchi, Mauro Magnani, Alessandro Isidori, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1675.
https://doi.org/10.1182/blood.V126.23.1675.1675
Published: 2015
Journal Articles

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Clinical Trials & Observations
Giuseppe Visani, Pietro Maria Stefani, Saveria Capria, Lara Malerba, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filippo Gherlinzoni, Roberta Gonella, Marco Gobbi, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Maria Dolores Caballero, Federica Loscocco, Alessandro Isidori
Journal: Blood
Blood (2014) 124 (19): 3029–3031.
https://doi.org/10.1182/blood-2014-08-596668
Published: 2014
Journal Articles

The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome

Alessandro Isidori, MD, PhD, Annamaria Ruzzo, PhD, Federica Loscocco, Maria Teresa Voso, M.D., Francesco Graziano, Sara Barulli, Emanuele Canestrari, Antonio Volpe, MD, Domenico Magro, MD, Pier Paolo Piccaluga, MD, PhD, Fabio Fuligni, Stefania Paolini, Teresa Ricciardi, Paola Picardi, Elisa Giacomini, Marco Rocchi, Mauro Magnani, Giuseppe Visani, MD
Journal: Blood
Blood (2013) 122 (21): 2815.
https://doi.org/10.1182/blood.V122.21.2815.2815
Published: 2013
Journal Articles

Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Giuseppe Visani, MD, Pietro Maria Stefani, Saveria Capria, MD, Lara Malerba, Piero Galieni, MD, Francesco Gaudio, Giorgina Specchia, MD, Giovanna Meloni, Filippo Gherlinzoni, MD, Claudio Giardini, MD, Sadia Falcioni, Roberta Gonella, Francesca Cuberli, Marco Gobbi, MD, Barbara Sarina, MD, Armando Santoro, MD, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Maria Dolores Caballero, Paola Picardi, Teresa Ricciardi, Federica Loscocco, Alessandro Isidori, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 2134.
https://doi.org/10.1182/blood.V122.21.2134.2134
Published: 2013
Journal Articles

Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients

Giuseppe Visani, MD, Francesco Di Raimondo, MD, Felicetto Ferrara, MD, Federica Loscocco, Pier Paolo Piccaluga, Fabio Fuligni, Anna Gazzola, PhD, Maura Rossi, Antonella Laginestra, Maria Rita Caraci, Cira Riccardi, Axel Visani, Sara Barulli, Barbara Guiducci, Teresa Ricciardi, Giovanni Sparaventi, Marco Rocchi, Alessandro Isidori, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 496.
https://doi.org/10.1182/blood.V122.21.496.496
Published: 2013
Journal Articles

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Clinical Trials & Observations
Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, Saveria Capria, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, Filippo Gherlinzoni, Claudio Giardini, Sadia Falcioni, Francesca Cuberli, Marco Gobbi, Barbara Sarina, Armando Santoro, Felicetto Ferrara, Marco Rocchi, Enrique M. Ocio, Maria Dolores Caballero, Alessandro Isidori
Journal: Blood
Blood (2011) 118 (12): 3419–3425.
https://doi.org/10.1182/blood-2011-04-351924
Published: 2011
Journal Articles

A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, Saveria Capria, Piero Galieni, Francesco Gaudio, Giorgina Specchia, Giovanna Meloni, MD, Filippo Gherlinzoni, MD, Claudio Giardini, Sadia Falcioni, Federica Loscocco, Francesca Cuberli, Marco Gobbi, MD, Armando Santoro, Barbara Sarina, Marco Rocchi, Alessandro Isidori, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 31.
https://doi.org/10.1182/blood.V116.21.31.31
Published: 2010
Journal Articles

A novel High dose chemotherapy strategy with Bendamustine in Adjunct to Etoposide, Aracytin and Melphalan (BeEAM) Followed by Autologous Stem cell rescue in Resistant/Relapsed Hodgkin and Non-Hodgkin Lymphoma Patients: a Phase I Study.

Giuseppe Visani, MD, Lara Malerba, MD, Piero Galieni, MD, Claudio Giardini, MD, Sadia Falcioni, MD, Marco Rocchi, Alessandro Isidori, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 4351.
https://doi.org/10.1182/blood.V114.22.4351.4351
Published: 2009